Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia.

A company spokesperson told Contract Pharma that the R&D agreement is with a company headquartered in Sweden with product development and regulatory affairs offices in the Netherlands and a product development and manufacturing plant in Putnam, CT. 

The research project includes analytical testing services and small batch pre-clinical proof of concept extrusion trials to determine drug release and stability.

“Alongside our development of SP-26, our novel time-release topical formulation of ketamine, we are beginning to explore an additional option for treating fibromyalgia using ketamine-loaded implants,” said Eric Weisblum, CEO of Silo Pharma. “The outcome of this research will provide additional information and data for our ongoing studies of ketamine treatments for fibromyalgia and other chronic pain indications.”

Fibromyalgia is a chronic condition causing widespread musculoskeletal pain accompanied by memory issues, sleep problems, and fatigue.